(Source: Jay Campbell) 📣 Quick Takeaways - AOD-9604 is a fragment of the human growth hormone (hGH) molecule engineered specifically for fat metabolism without the growth-promoting or blood sugar disrupting effects sometimes experienced with HGH - Optimal dosing is 250-500 mcg daily, administered subcutaneously in a fasted state for maximum lipolytic effect - Stacking with secretagogues or GLP-1 agonists significantly amplifies results - Expect meaningful changes in 8 to 12 weeks IF diet, sleep, and hormones are already dialed in ❇️ What AOD-9604 Actually Is AOD-9604, short for Anti-Obesity Drug 9604, is a synthetic peptide corresponding to amino acids 176 to 191 on the C-terminal end of the human growth hormone molecule. But it’s so much more than a fragment or a watered-down version of growth hormone. This specific region of the hGH structure is responsible for the fat-burning activity of the full molecule, but it does NOT interact with the IGF-1 receptor the way the original HGH molecule does. ❇️ Why does this matter? Full exogenous HGH at therapeutic or supraphysiological doses can elevate blood glucose and blunt insulin sensitivity, while driving acromegaly-like side effects in susceptible individuals over time. And since it never activates IGF-1-dependent signaling pathways, AOD-9604 gets to avoid inducing these side effects. What it does instead is bind to a beta-3 adrenergic receptor pathway responsible for directly stimulating lipolysis (i.e. the breakdown of stored triglycerides in fat cells) while simultaneously inhibiting lipogenesis (the creation of new fat cell). ➡ This dual-threat mechanism is why people who have “tried everything” still end up responding well to AOD-9604. ❇️ Why Mainstream Medicine Ignores This Peptide The story of AOD-9604 is a perfect case study of how the sick-care system works against health optimization:

❇️ If there's one organ that best illustrates the concept of biological aging, it's the thymus. Peak thymic function occurs in childhood; by puberty, involution has already begun; by age 40, most of the thymus has been replaced by fatty tissue; by 70, it's nearly gone. The immune consequences of this shrinkage play out over decades — declining T-cell diversity, reduced adaptive immune response, and growing vulnerability to infection and immune dysregulation. Thymagen is a dipeptide bioregulator from the Khavinson series designed to address thymic aging at the gene expression level, and in the context of longevity research, few targets matter more. ❇️ What Is Thymagen? Thymagen (also referred to as Timagen) is a short-chain dipeptide bioregulator (Lys-Glu) developed at the St. Petersburg Institute of Bioregulation and Gerontology, targeting thymic epithelial cells — the stromal cells that form the thymic microenvironment where T-lymphocytes mature and are selected. This places it in the same organ-specific Khavinson series as the other bioregulators we've covered, but with a uniquely systemic reach: immune function isn't confined to one organ or tissue, so a thymic bioregulator has downstream effects across the entire body. 👉🏼 It's worth distinguishing Thymagen from Thymalin, a related but distinct compound. Thymalin is a polypeptide complex extracted from calf thymus tissue — a broader, multi-peptide preparation. Thymagen is a defined, synthetic dipeptide with a specific sequence (Lys-Glu), making it more amenable to precise research characterization. Both target thymic function, but Thymagen represents the refined, single-compound iteration of that approach. ❇️ Why the Thymus Is Central to Longevity Research The thymus is the organ where naive T-cells undergo maturation, education, and selection — a process that generates the diverse, self-tolerant T-cell repertoire the adaptive immune system depends on. As thymic involution progresses, the output of new naive T-cells drops dramatically, and the peripheral T-cell pool becomes increasingly dominated by old, clonally expanded memory cells with narrowing antigen specificity. This phenomenon — called immunosenescence — is directly linked to increased susceptibility to novel pathogens, reduced vaccine efficacy, chronic low-grade inflammation (inflammaging), and rising rates of autoimmunity and cancer immune escape in older adults. Reversing or slowing thymic involution is therefore one of the highest-leverage interventions in aging biology.